Internal link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial June 08, 2017 at 01:03 PM UTC
Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 May 31, 2017 at 11:00 AM UTC
Internal link ProQR remembers co-founder Henri Termeer after his unexpected passing May 15, 2017 at 11:00 AM UTC
Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome May 01, 2017 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients April 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Deutsche Bank Health Care Conference April 20, 2017 at 11:00 AM UTC
Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU April 03, 2017 at 11:00 AM UTC
Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer March 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in March March 01, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update February 28, 2017 at 12:00 PM UTC
Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day February 27, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference February 07, 2017 at 12:00 PM UTC